VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

PROSCA/BLADDR 2020 | PSMA-PET for patients with high-risk for de novo N1 disease

Jeremie Calais, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA, explores the use of PSMA-PET in high-risk de novo N1 prostate cancer, and whether its use makes a difference for this patient population. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter